338 related articles for article (PubMed ID: 35095765)
21. Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1.
Ogawa E; Furusyo N; Murata M; Ikezaki H; Ihara T; Hayashi T; Toyoda K; Taniai H; Okada K; Kainuma M; Hayashi J
J Hepatol; 2012 Sep; 57(3):534-40. PubMed ID: 22613000
[TBL] [Abstract][Full Text] [Related]
22. Meta-analysis: insulin resistance and sustained virological response in hepatitis C.
Eslam M; Aparcero R; Kawaguchi T; Del Campo JA; Sata M; Khattab MA; Romero-Gomez M
Aliment Pharmacol Ther; 2011 Aug; 34(3):297-305. PubMed ID: 21623851
[TBL] [Abstract][Full Text] [Related]
23. Insulin resistance predicts sustained virological response to treatment of chronic hepatitis C independently of the IL28b rs12979860 polymorphism.
Del Campo JA; Ampuero J; Rojas L; Conde M; Rojas A; Maraver M; Millán R; García-Valdecasas M; García-Lozano JR; González-Escribano MF; Romero-Gómez M
Aliment Pharmacol Ther; 2013 Jan; 37(1):74-80. PubMed ID: 23121166
[TBL] [Abstract][Full Text] [Related]
24. The association of hepatitis c virus infection status with serum glucose levels.
Li Y; Wang X; Yu G; Sun H; Lv J; Chi X; Wu R; Gao X; Niu J
BMC Gastroenterol; 2019 Jun; 19(1):86. PubMed ID: 31195990
[TBL] [Abstract][Full Text] [Related]
25. Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin.
Grasso A; Malfatti F; De Leo P; Martines H; Fabris P; Toscanini F; Anselmo M; Menardo G
J Hepatol; 2009 Dec; 51(6):984-90. PubMed ID: 19695729
[TBL] [Abstract][Full Text] [Related]
26. Assessment of factors affecting response of direct-acting antivirals in chronic hepatitis C patients.
Jain N; Garg R; Singh GP; Kaur S; Chawla SPS; Padda P
Ann Afr Med; 2023; 22(4):456-464. PubMed ID: 38358146
[TBL] [Abstract][Full Text] [Related]
27. Adipokines and insulin resistance, predictors of response to therapy in Egyptian patients with chronic hepatitis C virus genotype 4.
Saad Y; Ahmed A; Saleh DA; Doss W
Eur J Gastroenterol Hepatol; 2013 Aug; 25(8):920-5. PubMed ID: 23442415
[TBL] [Abstract][Full Text] [Related]
28. Prevalence of
Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
[TBL] [Abstract][Full Text] [Related]
30. Sustained virological response prevents the development of insulin resistance in patients with chronic hepatitis C.
Aghemo A; Prati GM; Rumi MG; Soffredini R; D'Ambrosio R; Orsi E; De Nicola S; Degasperi E; Grancini V; Colombo M
Hepatology; 2012 Nov; 56(5):1681-7. PubMed ID: 22619107
[TBL] [Abstract][Full Text] [Related]
31. Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia.
Tsertsvadze T; Gamkrelidze A; Nasrullah M; Sharvadze L; Morgan J; Shadaker S; Gvinjilia L; Butsashvili M; Metreveli D; Kerashvili V; Ezugbaia M; Chkhartishvili N; Abutidze A; Kvaratskhelia V; Averhoff F
BMC Infect Dis; 2020 Jan; 20(1):30. PubMed ID: 31924172
[TBL] [Abstract][Full Text] [Related]
32. Lipids, glucose and iron metabolic alterations in chronic hepatitis C after viral eradication - comparison of the new direct-acting antiviral agents with the old regimens.
Carvalho JR; Velosa J; Serejo F
Scand J Gastroenterol; 2018; 53(7):857-863. PubMed ID: 29779403
[TBL] [Abstract][Full Text] [Related]
33. The impact of direct-acting antiviral treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients: temporary? permanent?
Özdoğan O; Yaraş S; Ateş F; Üçbilek E; Sezgin O; Altıntaş E
Turk J Gastroenterol; 2020 May; 31(5):384-392. PubMed ID: 32519958
[TBL] [Abstract][Full Text] [Related]
34. CURING HEPATITIS C WITH THE NEW DIRECT ACTING ANTIVIRALS DID NOT IMPROVE INSULIN RESISTANCE AFTER ONE YEAR.
Strauhs-Nitsch L; Campiolo MF; Morsoletto DBG; Pissaia Junior A; Ivantes CAP
Arq Gastroenterol; 2020; 57(3):267-271. PubMed ID: 33027477
[TBL] [Abstract][Full Text] [Related]
35. Chronic hepatitis C infection is associated with insulin resistance and lipid profiles.
Dai CY; Yeh ML; Huang CF; Hou CH; Hsieh MY; Huang JF; Lin IL; Lin ZY; Chen SC; Wang LY; Chuang WL; Yu ML; Tung HD
J Gastroenterol Hepatol; 2015 May; 30(5):879-84. PubMed ID: 23808794
[TBL] [Abstract][Full Text] [Related]
36. Hepatic steatosis in genotype 4 chronic hepatitis C patients: implication for therapy.
Khattab MA; Abdel-fattah ME; Eslam M; Abdelaleem A; Abdelaleem RA; Shatat M; Ali A; Hamdy L; Tawfek H
J Clin Gastroenterol; 2010; 44(10):707-12. PubMed ID: 20195166
[TBL] [Abstract][Full Text] [Related]
37. Insulin resistance as a predictor of early virologic response to HCV therapy among chronic HCV Egyptian patients.
Abd El-Wahab EW; Mikheal A; Sidkey F; Shatat HZ
J Med Virol; 2015 Mar; 87(3):428-40. PubMed ID: 25583244
[TBL] [Abstract][Full Text] [Related]
38. Study of changes in lipid profile and insulin resistance in Egyptian patients with chronic hepatitis C genotype 4 in the era of DAAs.
El Sagheer G; Soliman E; Ahmad A; Hamdy L
Libyan J Med; 2018 Dec; 13(1):1435124. PubMed ID: 29451090
[TBL] [Abstract][Full Text] [Related]
39. Association between Leptin and Complement in Hepatitis C Patients with Viral Clearance: Homeostasis of Metabolism and Immunity.
Chang ML; Kuo CJ; Huang HC; Chu YY; Chiu CT
PLoS One; 2016; 11(11):e0166712. PubMed ID: 27870883
[TBL] [Abstract][Full Text] [Related]
40. Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C.
Jian Wu Y; Shu Chen L; Gui Qiang W
Liver Int; 2006 Mar; 26(2):166-72. PubMed ID: 16448454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
